Escitalopram in Schizophrenia in OCD- Open Label Study

Schizophrenia Clinical Trial

Official title:

Escitalopram in the Treatment of Patient Suffering From Scizophrenia and Obsessive Compulsive Disorder- an Open Label Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00456937
• Other study ID #: Escitalopram-173CTIL
• Status: Completed
• Phase: Phase 4
• First received: December 3, 2006
• Last updated: January 26, 2009
• Start date: July 2006
• Est. completion date: September 2008

Study information

• Verified date: January 2009
• Source: BeerYaakov Mental Health Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationIsrael: Israeli Health Ministry Pharmaceutical Administration
• Study type: Interventional

Clinical Trial Summary

SSRI's has been demonstrated to be partially effective in schizophrenia and OCD. We therefore suggest that Escitalopram up to 20 mg /d in those patients could be effective in reducing obsessive compulsive symptomatology

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: September 2008
• Est. primary completion date: September 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients who suffer from schizophrenia and OCD

Exclusion Criteria:

• Substance abuse,

• Serious medical condintions,

• Being on SSRI treatment

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Obsessive-Compulsive Disorder
• Schizophrenia

Intervention

Drug:
• Escitalopram

Locations

Country	Name	City	State
Israel	Beer Yaakov MHC	Beer Yaakov

Sponsors (2)

Lead Sponsor	Collaborator
BeerYaakov Mental Health Center	Lundbeck Israel

Country where clinical trial is conducted

Israel,